The US Food and Drug Administration (FDA) has approved teriflunomide to treat relapsing forms of multiple sclerosis (MS), making it the second oral agent approved for this indication. (Fingolimod was the first oral treatment approved in September 2010 for relapsing MS. Since then, changes have been made to the label to reflect FDA concerns about [...]
Honey may be a preferable treatment of cough and sleep difficulties associated with childhood URI
The US Food and Drug Administration (FDA) has approved pregabalin (Lyrica, Pfizer Inc.) for the management of neuropathic pain associated with spinal cord injury.
FOOD BUSINESS OPERATOR The Food Safety and Standards Act. 2006 has come into force with effect from 05th August. 2011. It defines a Food Business Operator (FBO) as a person engaged in the business of food manufacture, processing, packaging, transportation, distribution, storage and import etc. and includes food services, catering services and sale of food [...]
Vitamin K for Osteoporosis
Mifepristone is used to control high blood sugar levels (hyperglycemia) in adults with endogenous Cushing’s syndrome. Endogenous Cushing’s syndrome is a serious, debilitating and rare multisystem disorder. It is caused by the overproduction of cortisol (a steroid hormone that increases blood sugar levels) by the adrenal glands. This syndrome most commonly affects adults between the [...]
There may soon be changes in the labeling of widely-used cholesterol-lowering drugs –STATINS sold in the country . The US Food and Drug Administration (FDA) warned that patients taking statins may face a “small increased risk” of higher blood-sugar levels and diabetes. Statins, when used with diet and exercise, help to lower a person’s “bad” cholesterol [...]
Taking antihypertensive medications at bedtime rather than in the morning has been shown to be associated with an increase in bedtime blood pressure (BP) decline toward a dipping pattern and better BP control and reduction in urinary protein excretion. Nocturnal hypertension is more common among patients with chronic kidney disease (CKD) who may thus experience greater effects of time medications for hypertension.
The US Food and Drug Administration (FDA) approved a once-daily bronchodilator — indacaterol maleat for chronic obstructive pulmonary disease (COPD). This bronchodilator may offer better patient adherence than twice-a-day bronchodilators on the market.
The FDA has issued a safety announcement to underline the increased risk for lower cognitive test scores among children born to mothers taking the antiseizure medication valproate sodium or the related products valproic acid and divalproex sodium during pregnancy, relative to other antiepileptic medications.